Upcoming Financial Report from SeaStar Medical
SeaStar Medical Holding Corporation (Nasdaq: ICU) is all set to unveil its financial results for the fourth quarter and year-end of 2024. The reporting will occur shortly after market close, scheduled for Thursday, March 27. This event is crucial for stakeholders eager to gauge the company's advancements and strategies in the healthcare sector, particularly as it focuses on combating conditions that pose severe risks to critically ill patients.
Event Details
On March 27 at 4:30 p.m. ET / 1:30 p.m. PT, SeaStar will initiate a conference call plus a live webcast to present its results. These discussions will provide valuable context around the performance metrics and business developments that have influenced the company’s trajectory throughout the year.
To access the live call, participants can dial 1 (800) 715-9871 if calling within the U.S., or 1 (646) 307-1963 from outside the U.S. This accessibility allows both investors and interested parties to stay informed about the distinct shifts and future direction of SeaStar Medical.
Replay Availability
For those who cannot participate live, there will be options to listen to a replay of the event after 7:30 p.m. ET. The replay will be accessible online via a webcast, making it easier for stakeholders to catch up on the insights shared during the call.
About SeaStar Medical
SeaStar Medical is revolutionizing healthcare for critically ill patients by focusing on treatments tailored for those facing organ failure, significantly raising the stakes in critical care. Recently, the company's product, QUELIMMUNE (SCD-PED), received approval from the U.S. Food and Drug Administration (FDA), marking a major milestone as it becomes the first FDA-approved treatment for life-threatening acute kidney injury (AKI) in pediatric patients. This condition often arises from septic conditions, underlining the urgency of innovative medical solutions in critical environments.
In addition to the recent FDA approval, SeaStar’s pioneering Selective Cytopheretic Device (SCD) therapy has obtained Breakthrough Device Designation, a testament to its potential in providing effective solutions across multiple therapeutic indications. This designation opens doors for expedited approval processes, enhancing the accessibility of advanced treatments for patients who desperately need them.
Pivotal Clinical Trials
Currently, the company is leading a clinical trial focusing on adult patients with AKI who require continuous renal replacement therapy. This critical condition affects over 200,000 adults annually in the U.S., and SeaStar is dedicated to addressing the pressing need for effective treatment options. The outcomes from this trial could have profound implications for patient care standards and treatment protocols in similar scenarios.
Company Mission and Future Outlook
SeaStar Medical remains committed to transforming critical care through innovation and evidence-based solutions. As they prepare to announce their quarterly results, stakeholders will be keenly analyzing how these developments align with the broader vision of improving outcomes for critically ill patients.
To learn more about SeaStar Medical's advancements and corporate strategy, you can visit their official website. The dynamic landscape of healthcare continues to evolve rapidly, and companies like SeaStar are at the forefront of bringing life-saving treatments to those in need.
Frequently Asked Questions
What is the purpose of the upcoming financial report?
The financial report aims to provide insights into SeaStar Medical’s performance and advancements over the past year, particularly in their treatment of critical conditions.
When will the financial results be announced?
The results will be announced on March 27 after market close.
How can I access the conference call?
Participants can access the call by dialing 1 (800) 715-9871 in the U.S. or 1 (646) 307-1963 from outside the U.S.
What is QUELIMMUNE?
QUELIMMUNE (SCD-PED) is SeaStar's FDA-approved treatment specifically for life-threatening acute kidney injury in critically ill pediatric patients.
Why is Breakthrough Device Designation important?
This designation accelerates the approval process for groundbreaking medical devices, allowing for quicker access to innovative treatments for patients in need.
